First-in-class drugs for chronic pulmonary disorders

Respivert developed a pipeline of novel, narrow spectrum, kinase inhibitors, that possessed a unique anti-inflammatory profile, and which were being developed as first-in-class treatments for moderate to severe asthma, COPD and cystic fibrosis.

CEO  Garth Rapeport

Advent Contact  Shahzad Malik

Advent invested in the Series A in 2007. Respivert was acquired by Centocor Ortho Biotech, a division of Johnson & Johnson in 2010.
Exited Investments
1 June 2010 in Press Release, Respivert

Advent Sells Respivert to J&J for Significant Cash Return

Press Release.   Advent Venture Partners was instrumental in the development of RespiVert, a true example of a classic venture investment and a case study of Advent‘s ability to find…
Read More